NASDAQ:APLS Apellis Pharmaceuticals - APLS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $54.77 -1.96 (-3.45%) (As of 02/3/2023 09:03 PM ET) Add Compare Share Share Today's Range$54.76▼$56.9550-Day Range$46.59▼$56.7352-Week Range$33.32▼$70.00Volume1.31 million shsAverage Volume1.25 million shsMarket Capitalization$6.06 billionP/E RatioN/ADividend YieldN/APrice Target$71.23 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Apellis Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.62 Rating ScoreUpside/Downside30.1% Upside$71.23 Price TargetShort InterestBearish8.67% of Shares Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.74Based on 8 Articles This WeekInsider TradingSelling Shares$4.28 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.28) to ($4.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector266th out of 1,025 stocksPharmaceutical Preparations Industry125th out of 498 stocks 3.3 Analyst's Opinion Consensus RatingApellis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.62, and is based on 7 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.23, Apellis Pharmaceuticals has a forecasted upside of 30.1% from its current price of $54.77.Amount of Analyst CoverageApellis Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.67% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently increased by 4.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Apellis Pharmaceuticals is -1.27. Previous Next 3.7 News and Social Media Coverage News SentimentApellis Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Apellis Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest6 people have searched for APLS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows7 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,281,175.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions87.26% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($6.28) to ($4.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -8.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -8.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 26.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Apellis Pharmaceuticals (NASDAQ:APLS) StockApellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.Read More Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Stock News HeadlinesFebruary 3, 2023 | americanbankingnews.comApellis Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:APLS)February 1, 2023 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $46,587.08 in StockFebruary 6, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 28, 2023 | americanbankingnews.comKaren Lewis Sells 2,955 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockDecember 16, 2022 | finance.yahoo.comApellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic AtrophyDecember 7, 2022 | finance.yahoo.comApellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?November 29, 2022 | barrons.comPremarket Movers: Elbit Systems, CME Group Cl A, Apellis PharmaceuticalsNovember 18, 2022 | benzinga.comLooking At Apellis Pharmaceuticals's Recent Unusual Options ActivityFebruary 6, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! November 18, 2022 | marketwatch.comApellis Shares Jump Premarket as FDA Accepts Amendment >APLSNovember 18, 2022 | markets.businessinsider.comApellis : FDA Accepts Pegcetacoplan NDA Amendment For Geographic Atrophy; Stock UpNovember 18, 2022 | finance.yahoo.comApellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)November 8, 2022 | markets.businessinsider.com5 Analysts Have This to Say About Apellis PharmaceuticalsOctober 16, 2022 | seekingalpha.comCiti lists four more value-creating events in biotech for this yearOctober 12, 2022 | finance.yahoo.comCorcept (CORT) Begins Phase II Study on Dazucorilant for ALSOctober 3, 2022 | finance.yahoo.comWhy Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers TodaySeptember 8, 2022 | markets.businessinsider.comStifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To KnowSeptember 7, 2022 | seekingalpha.comIveric bio: Further Upside Possible Based On Expanded Opportunities With ZimuraSeptember 1, 2022 | finance.yahoo.comApellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two YearsAugust 24, 2022 | msn.comApellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder StudyAugust 24, 2022 | seekingalpha.comApellis stock rises as 2-year data of pegcetacoplan for eye disorder shows promiseAugust 24, 2022 | finance.yahoo.comApellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)August 8, 2022 | seekingalpha.comApellis Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationAugust 8, 2022 | seekingalpha.comApellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2022 Results - Earnings Call TranscriptAugust 8, 2022 | finance.yahoo.comApellis Pharmaceuticals Reports Second Quarter 2022 Financial ResultsJuly 19, 2022 | msn.comApellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority ReviewJuly 19, 2022 | finance.yahoo.comApellis Pharmaceuticals Stock Jumps After FDA Accepts Drug for ReviewSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Company Calendar Last Earnings11/08/2021Today2/06/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLS CUSIPN/A CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees476Year FoundedN/APrice Target and Rating Average Stock Price Forecast$71.23 High Stock Price Forecast$123.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+30.1%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($6.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-746,350,000.00 Net Margins-560.92% Pretax Margin-558.72% Return on Equity-194.70% Return on Assets-64.99% Debt Debt-to-Equity Ratio0.30 Current Ratio7.21 Quick Ratio6.69 Sales & Book Value Annual Sales$113.05 million Price / Sales53.57 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book26.85Miscellaneous Outstanding Shares110,576,000Free Float101,730,000Market Cap$6.06 billion OptionableNot Optionable Beta1.20 Key ExecutivesCedric FrancoisPresident, Chief Executive Officer & DirectorTimothy Eugene SullivanChief Financial Officer & TreasurerPascal DeschateletsChief Scientific OfficerNur NicholsonChief Technical Operations OfficerCaroline BaumalChief Medical OfficerKey CompetitorsRoivant SciencesNASDAQ:ROIVGrifolsNASDAQ:GRFSIonis PharmaceuticalsNASDAQ:IONSElanco Animal HealthNYSE:ELANKaruna TherapeuticsNASDAQ:KRTXView All CompetitorsInsiders & InstitutionsEFG Asset Management North America Corp.Sold 1,955 shares on 2/3/2023Ownership: 0.023%Illinois Municipal Retirement FundBought 8,694 shares on 2/3/2023Ownership: 0.008%ProShare Advisors LLCBought 1,569 shares on 2/2/2023Ownership: 0.020%Profund Advisors LLCBought 315 shares on 2/2/2023Ownership: 0.012%Stock Yards Bank & Trust Co.Bought 1,715 shares on 2/2/2023Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions APLS Stock - Frequently Asked Questions Should I buy or sell Apellis Pharmaceuticals stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APLS shares. View APLS analyst ratings or view top-rated stocks. What is Apellis Pharmaceuticals' stock price forecast for 2023? 13 brokerages have issued 12 month price targets for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $40.00 to $123.00. On average, they predict the company's stock price to reach $71.23 in the next year. This suggests a possible upside of 30.1% from the stock's current price. View analysts price targets for APLS or view top-rated stocks among Wall Street analysts. How have APLS shares performed in 2023? Apellis Pharmaceuticals' stock was trading at $51.71 at the start of the year. Since then, APLS shares have increased by 5.9% and is now trading at $54.77. View the best growth stocks for 2023 here. When is Apellis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our APLS earnings forecast. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its earnings results on Monday, November, 7th. The company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.48) by $0.27. The firm had revenue of $22.06 million for the quarter, compared to analysts' expectations of $19.82 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 194.70% and a negative net margin of 560.92%. What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO? 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI). When did Apellis Pharmaceuticals IPO? (APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO. What is Apellis Pharmaceuticals' stock symbol? Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS." Who are Apellis Pharmaceuticals' major shareholders? Apellis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.66%), Allspring Global Investments Holdings LLC (0.11%), New York State Common Retirement Fund (0.09%), Bank of Montreal Can (0.09%), Comerica Bank (0.06%) and State of New Jersey Common Pension Fund D (0.05%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets, Victoria L Brown and Victoria L Brown. View institutional ownership trends. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Apellis Pharmaceuticals' stock price today? One share of APLS stock can currently be purchased for approximately $54.77. How much money does Apellis Pharmaceuticals make? Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $6.06 billion and generates $113.05 million in revenue each year. The company earns $-746,350,000.00 in net income (profit) each year or ($6.24) on an earnings per share basis. How many employees does Apellis Pharmaceuticals have? The company employs 476 workers across the globe. How can I contact Apellis Pharmaceuticals? Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com. This page (NASDAQ:APLS) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.